Evoke Pharma, Inc. (EVOK)

NASDAQ: EVOK · IEX Real-Time Price · USD
3.04
+0.15 (5.19%)
At close: Jun 24, 2022 4:00 PM
3.03
-0.01 (-0.33%)
After-hours: Jun 24, 2022 5:41 PM EDT
5.19%
Market Cap 10.16M
Revenue (ttm) 1.95M
Net Income (ttm) -8.11M
Shares Out 3.34M
EPS (ttm) -2.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date May 23, 2022
Volume 290,310
Open 2.98
Previous Close 2.89
Day's Range 2.94 - 3.35
52-Week Range 2.03 - 18.96
Beta 0.78
Analysts Buy
Price Target 79.56 (+2,517.1%)
Earnings Date Aug 11, 2022

About EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incor... [Read more...]

Industry Pharmaceuticals
IPO Date Sep 25, 2013
CEO David Gonyer
Employees 4
Stock Exchange NASDAQ
Ticker Symbol EVOK
Full Company Profile

Financial Performance

In 2021, Evoke Pharma's revenue was $1.62 million, an increase of 6,929.00% compared to the previous year's $23,020. Losses were -$8.54 million, -35.10% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for EVOK stock is "Buy." The 12-month stock price forecast is 79.56, which is an increase of 2,517.11% from the latest price.

Price Target
$79.56
(2,517.11% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Biotech Penny Stocks Investing Guide

What to know about trading biotech stocks in 2022 The post Biotech Penny Stocks Investing Guide appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: RIGLZOM

Why These 3 Penny Stocks Exploded Today

Why these three penny stocks exploded during trading today The post Why These 3 Penny Stocks Exploded Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: SIDU

Evoke Pharma (EVOK) Stock Soars 50% on Medicaid Drug Approval

Evoke Pharma (EVOK) stock is rocketing higher on Wednesday after the company got Medicaid approval for its GIMOTI nasal spray. The post Evoke Pharma (EVOK) Stock Soars 50% on Medicaid Drug Approval appe...

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

SOLANA BEACH, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an e...

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

SOLANA BEACH, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an e...

Real-World Data Analysis Reveals a Lower Risk of Tardive Dyskinesia (TD) with Metoclopramide than Previously Reported

Presented as a Poster of Distinction at Digestive Disease Week (DDW) 2022, showed a 98.8 per 100,000 (0.1%) incidence of TD among gastroparesis patients treated with metoclopramide

Penny Stocks To Buy Now? 6 To Watch Under $1 This Week

Penny stocks to watch under $1 today. The post Penny Stocks To Buy Now?

Other symbols: ACSTGFAIMKDRIBT

Penny Stocks To Buy Now? 4 To Watch Under $1 This Week

Penny stocks to watch under $1 today. The post Penny Stocks To Buy Now?

Other symbols: MKDNISN

10 Top Penny Stocks To Buy For Under $1 May 2022 Edition

Top penny stocks under $1 to watch in May. The post 10 Top Penny Stocks To Buy For Under $1 May 2022 Edition appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Evoke Pharma to Report First Quarter 2022 Financial Results on May 10, 2022

SOLANA BEACH, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced tha...

3 Hot Penny Stocks to Watch as EVOK Stock Climbs 120%

Why these 3 penny stocks are climbing today The post 3 Hot Penny Stocks to Watch as EVOK Stock Climbs 120% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Other symbols: CEIGOVX

Why Is Evoke Pharma (EVOK) Stock Up 130% Today?

Evoke Pharma is up an unbelievable 130% today on news of recently granted drug exclusivity. How high will EVOK stock soar?

Evoke Shares Skyrocket On New FDA Market Exclusivity For Gimoti Nasal Spray

The FDA has granted new drug product exclusivity to Evoke Pharma Inc's (NASDAQ: EVOK) Gimoti (metoclopramide) nasal spray to relieve symptoms associated with acute and recurrent diabetic gastroparesis i...

Evoke Pharma Reports Fourth Quarter and Full Year 2021 Financial Results

Fourth-quarter net product sales from prescriptions increased by 46% to $361,000 versus Q3  Easing of COVID-19 restrictions helped fuel higher sales, increased face-to-face meetings with healthcare prof...

Evoke Pharma to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022

SOLANA BEACH, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced t...

Evoke Pharma and EVERSANA Announce Acceptance of Abstract for Poster of Distinction Presentation at Digestive Disease...

Revisiting the risk of tardive dyskinesia with metoclopramide use in diabetic gastroparesis: results of a real-world data driven epidemiology study Revisiting the risk of tardive dyskinesia with metoclo...

Evoke Pharma and EVERSANA Extend Commercialization Partnership to Further Support GIMOTI

SOLANA BEACH, Calif. and CHICAGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseas...

Evoke Pharma Reports Third Quarter 2021 Financial Results

SOLANA BEACH, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today an...

Evoke Pharma to Report Third Quarter 2021 Financial Results on November 10, 2021

SOLANA BEACH, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, toda...

Evoke Pharma's Commercial Partner EVERSANA, Receives PM360's Trailblazer Initiative Award for Innovation in Healthcar...

Award for “Spray Away” Campaign seeking to drive patient and provider awareness for the novel nasal spray treatment of symptoms of Diabetic Gastroparesis

Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced t...

What's Up With Evoke Pharma's Stock Popping Off Friday?

Evoke Pharma Inc (NASDAQ: EVOK) shares are trading higher by 23.1% at $1.38 after the company reported better-than-expected second-quarter EPS results. Evoke Pharma reported quarterly losses of 7 cents ...

Evoke Pharma Reports Second Quarter 2021 Financial Results

Approximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti ®

Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders' (IFFGD) Au...

Participating and Sponsorship in Upcoming Digestive Health Virtual Walk Participating and Sponsorship in Upcoming Digestive Health Virtual Walk

Evoke Pharma Launches Gimoti® Patient and Physician Experience Program

Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers Program intends to expand awareness and trial of GIMOTI among non-prescribing healthcare providers